Drug intelligence / Profile preview

OXC-201

Development stage: Preclinical
Lead developer: Oxcia
Modality: Small Molecules

Overview

OXC-201 is a first-in-class small molecule inhibitor of 8-oxoguanine DNA glycosylase-1 (OGG1) being developed by Oxcia AB. It is primarily targeted for the treatment of idiopathic pulmonary fibrosis (IPF) and other inflammatory and fibrosis-related diseases. The drug functions by inhibiting the binding of OGG1 to oxidative DNA lesions, which in turn blocks the modulation of gene transcription pathways that drive inflammation and fibrogenesis. OXC-201 is currently in preclinical development and has received support from the European Innovation Council (EIC) through the TOPFIBRO project, demonstrating superior efficacy compared to standard of care in ex vivo human lung tissue models.

Targets

OGG1 (8-oxoguanine DNA glycosylase)

Beyond the preview

Go deeper on OXC-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OXC-201.

Explore the full profile